Current Frontline Treatment of Diffuse Large B-Cell Lymphoma

• Published in: Oncology (Williston Park, N.Y.) Vol. 36; no. 1; pp. 51 - 58
• Main Authors: Spinner, Michael A, Advani, Ranjana H
• Format: Journal Article
• Language: English
• Published: United States Intellisphere, LLC 01.01.2022; MultiMedia Healthcare Inc
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; B cells; Biopsy; Bone marrow; Care and treatment; Classification; Corticosteroids; Cyclophosphamide; Cyclophosphamide - therapeutic use; Dose-Response Relationship, Drug; Doxorubicin - therapeutic use; Female; Gene expression; Geriatrics; Humans; Ibritumomab tiuxetan; Lymphoma; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - pathology; Male; Medical prognosis; Metabolism; Middle Aged; Mutation; Non-Hodgkin's lymphomas; Patients; Prednisone; Prednisone - therapeutic use; Radiation therapy; Rituximab - therapeutic use; Vincristine; Vincristine - therapeutic use
• ISSN: 0890-9091; 2767-7389
• DOI: 10.46883/2022.25920940

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is an aggressive and biologically heterogeneous disease. Risk stratification and treatment algorithms vary based on stage of disease and bulk along with other clinical and biological factors, including the International Prognostic Index, cell of origin, and other molecular subsets. Rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard of care and cures more than 60% of patients. The role of radiotherapy is largely restricted to patients with limited-stage disease. In elderly patients, geriatric assessments of baseline fitness and functional status help optimize therapy based on the balance of efficacy and toxicity. While numerous randomized trials have failed to improve upon R-CHOP, a recent press release from the POLARIX trial (NCT03274492) suggests that adding polatuzumab vedotin (Polivy) to rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) improves progression-free survival and may replace R-CHOP in eligible patients. Ongoing trials are exploring frontline therapy that integrates other novel agents, including various small molecules, bispecific antibodies, and chimeric antigen receptor T-cell therapy, with promising preliminary results. Defining a population of patients with high-risk disease in whom R-CHOP is not effective is critical. Patient selection based on refining molecular subsets, quantitative PET metrics such as metabolic tumor volume, and dynamic risk assessments using interim PET and circulating tumor DNA analysis may allow for a personalized, response-adapted approach that will further improve outcomes in DLBCL.